Acumen Pharmaceuticals, Inc. has received exclusive rights from its partner, Merck Sharp & Dohme Corp., (formerly Merck & Co., Inc.), for the joint anti-amyloid beta oligomers (Aβo) immunotherapy program, including preclinical candidate ACU193, a humanized monoclonal antibody targeting Aβo for the treatment of Alzheimer’s disease.

As part of this technology transfer, Acumen received all research materials, cell lines and data package reports and information related to the program. Acumen has no continuing or future financial obligations or rights due to Merck.